Technology Networks

Sirna Therapeutics

2950 Wilderness Place,
Boulder,
CO 80301
United States of America
Tel: (303) 449-6500
Fax: (303) 449-6995

Print Email to a friend

Sirna Therapeutics is a biotechnology company that is focused on developing therapeutics based on RNA interference (RNAi) technology, a promising field in biology and medicine. We use our proprietary technology and expertise in nucleic acid technology to develop a new class of nucleic acid RNAi-based therapeutics that target human diseases. We have over 10 years of experience in nucleic acid technology, and a broad portfolio of intellectual property in the nucleic acid technology field. We believe that our intellectual property position and nucleic acid expertise put us in a leading position for the development of RNAi-based therapeutics.

Further Information: http://www.sirna.com



Related news from our archive

Sirna Reports Final Results from Phase I Study on Therapeutic for age-related Macular Degeneration
100% visual acuity stabilization was observed in all patient groups eight weeks after a single dose of the RNAi-Based Therapeutic.

European Patent Office Limits Scope of Kreutzer-Limmer RNAi Patent Claim
Long-awaited ruling on Kreutzer-Limmer patent validates objections filed by Sirna, sanofi-aventis, Atugen, and others.

Sirna Announces Licensing Agreement with UMMS
License covers use of microRNA technology for therapeutics, diagnostics and laboratory reagents.

Sirna Announces Research Alliance with GSK
Sirna will provide GSK with optimized and formulated siRNAs against targets for respiratory diseases.

Sirna Reports Final Results from Phase I Study on Therapeutic for age-related Macular Degeneration
100% visual acuity stabilization was observed in all patient groups eight weeks after a single dose of the RNAi-Based Therapeutic.

European Patent Office Limits Scope of Kreutzer-Limmer RNAi Patent Claim
Long-awaited ruling on Kreutzer-Limmer patent validates objections filed by Sirna, sanofi-aventis, Atugen, and others.

Sirna Announces Licensing Agreement with UMMS
License covers use of microRNA technology for therapeutics, diagnostics and laboratory reagents.

Sirna Announces Research Alliance with GSK
Sirna will provide GSK with optimized and formulated siRNAs against targets for respiratory diseases.